Sunitinib in patients with metastatic renal cell carcinoma

JAMA

Volumn 295, Issue 21, 2006, Pages 2516-2524

  Motzer, Robert J ^a   Rini, Brian I ^b,c   Bukowski, Ronald M ^c   Curti, Brendan D ^d   George, Daniel J ^e   Hudes, Gary R ^f   Redman, Bruce G ^g   Margolin, Kim A ^h   Merchan, Jaime R ⁱ   Wilding, George ^j   Ginsberg, Michelle S ^a   Bacik, Jennifer ^a   Kim, Sindy T ^k   Baum, Charles M ^k   Michaelson, M Dror ^l  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d EARLE A CHILES RESEARCH INSTITUTE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF WISCONSIN   (United States)

^k PFIZER INC   (United States)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; SUNITINIB; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING;

EID: 33744954585     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.21.2516     Document Type: Article

References (24)

1. Curti B. Renal cell carcinoma. JAMA. 2004;292:97-100.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
3. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417.
4. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am. 1993;20:283-295.
5. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76:824-832.
6. Vogelzang NJ, Lipton A, Figlin RA, et al. Subcutaneous interleukin-2 plus interferon-alfa-2a in metastatic renal cancer. J Clin Oncol. 1993;11:1809-1816.
7. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463.
8. Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma. J Clin Oncol. 1999;17:2039-2043.
9. Kondo K, Yao M, Yoshida M, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma. Genes Chromosomes Cancer. 2002;34:58-68.
10. Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumorsuppressor gene. Exp Cell Res. 2001;264:117-125.
11. Kim W, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev. 2003;13:55-60.
12. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. Sunitinib inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471-478.
13. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597-3605.
14. O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase 1 clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003;9:5465-5476.
15. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Clin Cancer Res. 2003;9:327-337.
16. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25-35.
17. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
19. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29-41.
20. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
22. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Oral presentation delivered at: 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla.
23. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
24. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.